Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|October 12, 2016

Datwyler Invests in Delaware Plant

The company invested more than CHF 100 million in a new Delaware manufacturing plant.

On Oct. 11, 2016, Datwyler announced that it is investing more than CHF 100 million (approximately $101 million) in a new manufacturing plant in Delaware, US. The new plant will be used to manufacture elastomer components for injectable drug delivery systems. The company said construction on the new plant will most likely begin before the end of 2016, with production scheduled to begin in the first half of 2018. The plant is expected to provide jobs for approximately 120 employees. In a press announcement, the company said that this new plant will strengthen Datwyler’s position in the US market. The new plant will serve customers in three key business regions, the US, Europe, and Asia.

Source: Datwyler

 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.